AWARD-7 enrolled adult patients with T2D (A1c, 7.5%10.5%) and CKD stages 34 who were being treated with ACEi or ARBs and found that dulaglutide (0.75 or 1.5 mg subcutaneous once weekly) achieved similar glycemic control to insulin glargine but had significantly less eGFR decline (mean 0.7 vs 3.3 mL/min/1.73 m 2 , respectively
Both have gained global attention for their ability to potentially aid substantial weight loss
The SURMOUNT trials for tirzepatide showed average losses of up to 22.5% of body weight figures that were previously only achievable with bariatric surgery
Tirzepatide vs semaglutide 2.4 mg in non-diabetic obesity SURMOUNT-5 direct head-to-head, -20.2% vs -13.7% at 72 weeks: Aronne NEJM 2025
### 20mg Semaglutide Vial The 20mg vial is the best value per milligram for patients on stable maintenance doses
How to Safely Transition from Semaglutide to Tirzepatide A safe transition protocol typically involves stopping semaglutide, waiting a washout period of 37 days, and then starting tirzepatide at its lowest dose